Skip to main content
Fig. 4 | Future Journal of Pharmaceutical Sciences

Fig. 4

From: Comprehensive preclinical studies on the bioactivity of Orbignya phalerata Mart. (Babassu) and its derived products: a systematic review

Fig. 4

In vivo risk of bias assessment by domain. (legend) Domains: D1—sequence generation; D2—baseline characteristics; D3—allocation concealment; D4—random housing; D5—blinding (performance bias); D6—random outcome assessment; D7—blinding (detection bias); D8—incomplete outcome data; D9—selective outcome reporting; D10—other sources of bias. Yes: low risk; No: high risk; Unclear: uncertain risk [19]

Back to article page